Compare NIO Inc. (NIO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs TransMedics Group Inc — how do they compare? NIO Inc. trades at $3.65 (market cap $9.23B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: NIO Inc. is far larger — about 3× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| NIO | TMDX | |
|---|---|---|
Market Cap | $9.23B | $3.06B |
Sector | Consumer Cyclical | Technology |
52-Week High | $7.89 | $150.42 |
52-Week Low | $3.70 | $61.99 |
Enterprise Value | $7.13B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.79, down 0.26% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 revenue growth of 69.1% year-over-year to $4.74 billion (Seeking Alpha, 2026-09-03), but missed revenue expectations. Vehicle margins improved to 18.4%, and cash flow turned positive, yet net losses persist. Analyst consensus is mixed, with a $5.50 price target suggesting 45% upside from current levels.
Outlook: NIO shows operational progress with narrowing losses and brand diversification, but high debt and Chinese EV competition pose risks. The stock's low P/S ratio of 0.54 indicates potential undervaluation if profitability improves. Investors face volatility from macroeconomic headwinds and execution challenges in achieving sustained positive earnings.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
